公开(公告)号：US11957785B2

公开(公告)日：2024-04-16

申请号：US17346874

申请日：2021-06-14

申请人： Intelgenx Corp.

发明人： Rodolphe Obeid ,  Nadine Paiement ,  Erick Gonzalez-Labrada

IPC分类号： A61K9/00 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46

CPC分类号： A61K9/006 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61K9/0065 ,  A61K31/352 ,  A61K2300/00 ,  A61K31/05 ,  A61K2300/00

摘要： An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

公开(公告)号：US11602504B2

公开(公告)日：2023-03-14

申请号：US16383813

申请日：2019-04-15

申请人： Intelgenx Corp.

发明人： Carolin Madwar ,  Nadine Paiement ,  Rodolphe Obeid ,  Justin Conway ,  Erick Gonzalez-Labrada

IPC分类号： A61K9/70 ,  A61K31/352 ,  A61K31/47 ,  A61K9/00

摘要： Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.

公开(公告)号：US20210315802A1

公开(公告)日：2021-10-14

申请号：US17346874

申请日：2021-06-14

申请人： Intelgenx Corp.

发明人： Rodolphe Obeid ,  Nadine Paiement ,  Erick Gonzalez-Labrada

IPC分类号： A61K9/00 ,  A61K47/34 ,  A61K47/32 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/20 ,  A61K47/10 ,  A61K47/12 ,  A61K31/352 ,  A61K36/185 ,  A61K47/44 ,  A61K45/06 ,  A61K47/46 ,  A61K31/05

摘要： An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

公开(公告)号：US11033493B2

公开(公告)日：2021-06-15

申请号：US16110737

申请日：2018-08-23

申请人： Intelgenx Corp.

发明人： Rodolphe Obeid ,  Nadine Paiement ,  Erick Gonzalez-Labrada

IPC分类号： A61K9/00 ,  A61K47/34 ,  A61K47/32 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/20 ,  A61K47/10 ,  A61K47/12 ,  A61K31/352 ,  A61K36/185 ,  A61K47/44 ,  A61K45/06 ,  A61K47/46 ,  A61K31/05

摘要： An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.